Generative AI

#Abiologics #Artificial intelligence (AI) #Biologics #Generative AI #Synthetic biology

Abiologics launches with a new class of supranatural medicines

Abiologics, a Flagship Pioneering company, has launched to develop a new class of supranatural and programmable medicines called Synteins. Synteins are computationally-generated and synthesised with novel building blocks, potentially providing treatments across a wide range of diseases. Flagship has initially committed $50 million to advance the company’s platform and develop… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Generative AI #Regulatory

Adding value to regulatory intelligence with generative AI

There is limitless scope for generative AI to transform regulatory processes. But where to start? ArisGlobal’s Agnes Cwienczek and Renato Rjavec describe use cases where AI is already delivering tangible everyday benefits. As life sciences companies’ investments in regulatory data capture, enrichment and exchange continue to rise in line with… Read More

#Exclusive Content #Regulatory

#Antibodies #Antiverse #Artificial intelligence (AI) #Generative AI #Oncology

Advancing antibody cancer therapeutics with AI

Antiverse is an artificial intelligence (AI)-driven company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Murat Tunaboylu, Co-founder and CEO of Antiverse, speaks with Megan Thomas about how AI can advance therapeutic antibody design. Megan T: How is Antiverse using AI in… Read More

#Cancer Research #Exclusive Content

#Absci #Antibodies #Artificial intelligence (AI) #Biologics #Generative AI #Interview

The next generation of AI

Reece Armstrong speaks to Sean McClain, Founder & CEO of Absci, about the rise of generative AI in life sciences. The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications.  Last year, a lot of focus was placed on artificial intelligence (AI) both… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Digital solutions #Generative AI #Machine learning

Siloed use of Gen AI will limit its transformation potential

As long as drug discovery, development and commercialisation activities and budgets continue to be managed in isolation, and Generative AI projects applied in a piecemeal fashion to individual applications, the pharma industry risks inhibiting the technology’s broader potential. Daniel Jamieson, CEO & founder of Biorelate, sets out his vision for… Read More

#Exclusive Content

#Artificial intelligence (AI) #Generative AI #Inflammatory Bowel Disease #Insilico Medicine #Phase I trial

AI-designed PHD 1/2 inhibitor for bowel disease enters human trials

Insilico Medicine has initiated the first-in-human study for ISM5411, a poly hydroxylase domain (PHD) 1/2 inhibitor for the treatment of inflammatory bowel disease (IBD) designed by its generative AI platform. The company also plans to conduct global, multicentre Phase Ib trials in patients with ulcerative colitis… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Drug discovery #Generative AI

Can vertical AI advance cell and gene therapies? 

Andrew Busey, Co-Founder, Form Bio, discusses why vertical AI is set to reshape the cell and gene therapy sector. The once-fictional artificial intelligence (AI) depicted in literature and movies has transitioned into a tangible and easily accessible tool in our modern world. General AI tools such as ChatGPT have acted… Read More

#Exclusive Content

#AI #Biotech #Drug discovery #Generative AI

Genentech and NVIDIA partner to accelerate drug discovery with AI 

Biotechnology company Genentech has entered into a partnership with software group NVIDIA to use generative AI to discover and develop new therapeutics.   The collaboration will see experts from each company optimise and accelerate Genentech’s proprietary algorithms with goals to transform the discovery and development of new… Read More

#News

#Artificial intelligence (AI) #Evozyne #Funding #Generative AI #Investment

$81 million raised to advance generative AI for drug discovery

Evozyne has closed an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. “In its first three years, Evozyne proved it could deliver novel, high-performance proteins that solve critical problems in healthcare and sustainability. Our next three years will be… Read More

#Business & Investment #News

#AI #Drug discovery #Generative AI #Machine learning

Generative AI and drug discovery: webinar

The webinar ‘Generative AI: Turning drug discovery into a technological pursuit’ supported by Thermo Fisher Scientific and presented by Generate:Biomedicines will be free to attend on 12 October 9am EDT / 2pm BST / 3pm CEST. The webinar, hosted by DDW, will feature the expertise of Adam Root, Vice President,… Read More

#News

AI concept
#AI #Generative AI #Machine learning #Webinar

Webinar: How AI is transforming drug discovery

This webinar supported by Thermo Fisher Scientific and presented by Generate:Biomedicines will be free to attend on 12 October 9am EDT / 2pm BST / 3pm CEST. The webinar, hosted by DDW, will feature the expertise of Adam Root, Vice President, Protein Sciences at Generate:Biomedicines who will discuss how an… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #Generative AI #Webinar

Generative AI: Turning drug discovery into a technological pursuit

This webinar, supported by Thermo Fisher Scientific and presented by Generate:Biomedicines, is now available to view on-demand. The webinar, hosted by DDW, will feature the expertise of Adam Root, Vice President, Protein Sciences at Generate:Biomedicines who will discuss how an integrated approach of using Cryo-EM with ML methods has the… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#Webinars

#AI #Drug discovery #Generative AI #Machine learning #Webinar

Generative AI webinar: Turning drug discovery into a technological pursuit

This webinar supported by Thermo Fisher Scientific and presented by Generate:Biomedicines will be free to attend on 12 October 9am EDT / 2pm BST / 3pm CEST. The webinar, hosted by DDW, will feature the expertise of Adam Root, Vice President, Protein Sciences at Generate:Biomedicines who will discuss how an… Read More

#News

AI and drug discovery
#Etcembly #Generative AI #Immunotherapy #T cell receptor (TCR) #Therapeutics

Etcembly announces immunotherapy drug designed by AI 

British techbio Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of T cell receptor (TCR) therapeutics designed using generative AI.  The company’s lead therapeutic programme, ETC-101, is the world’s first AI-designed bispecific T cell engager. It targets PRAME, a validated antigen present… Read More

#Business & Investment #News

Workcell with a microfluidic chip testing thousands of AI-designed proteins
#Adaptyv Bio #AI #Automation / robotics #Enzymes #Generative AI #Life sciences #Protein engineering #Technology

A new paradigm for protein engineering 

Adaptyv Bio, a Swiss/US technology company that develops infrastructure and tools for protein designers to engineer better proteins, has built a protein engineering foundry that it says will “pave the way” for protein designers to develop new medicines, novel enzymes and sustainable materials. AI tools like ChatGPT… Read More

#News